Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial

What Was Tested

Researchers studied Tesamorelin and GHRH (Growth Hormone-Releasing Hormone) in this randomized controlled trial publication.

The objective of this study was to determine whether tesamorelin, a stabilized growth hormone-releasing hormone analogue, would alter insulin sensitivity or control of diabetes.

Who Took Part

The abstract describes 53 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

A 12-week randomized, placebo-controlled study of 53 patients with type 2 diabetes.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Tesamorelin and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Tesamorelin group a baseline to be compared against.

Fasting glucose, glucose and insulin from oral glucose tolerance test, glycosylated hemoglobin (HbA1c), home blood glucose, insulin-like growth factor-1, and lipids.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Growth Hormone-Releasing Hormone, Insulin Resistance, Insulin-Like Growth Factor I and Lipids.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone) in 53 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (PloS one), a journal based in United States.

More context: the Tesamorelin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.